Navigation Links
Decision Resources' Forecast of Global Tanezumab Sales Slashed Following FDA Halt of Phase III Studies
Date:10/26/2010

BURLINGTON, Mass., Oct. 26 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that because Phase III trials of Pfizer's tanezumab for the treatment of osteoarthritis pain were halted over U.S. Food & Drug Administration safety concerns, Decision Resources' Pharmaview 2016 global sales forecast for tanezumab has been reduced by $1.2 billion to $200 million. The decision to end the trial was made after a subset of patients in the trial required joint replacement surgery due to worsened conditions.

The discontinuation of the trial is a setback for the drug and a concern for the entire drug class, as tanezumab was the most clinically advanced agent of a family of anti-nerve growth factor (NGF) monoclonal antibodies (MAbs). Anti-NGF MAbs have garnered considerable attention from large pharmaceutical companies for the novel mechanism of action; Sanofi-Aventis (SAR164877), Johnson & Johnson (AMG-403) and Abbott (PG-110) are each in an early-stage program.

"With Lipitor, Celebrex and Viagra all facing patent expiries over the next several years, Pfizer greatly needs new agents to fill the revenue gap," said Pharmaview Analyst Michael Latwis, M.B.A. "Unfortunately, given that approval for osteoarthritis pain—the largest potential market for tanezumab—is highly unlikely, our Pharmaview model does not expect sales to reach anywhere near blockbuster status."

New Pharmaview Platform ReleasedDecision Resources has released a new delivery platform for its Pharmaview product. Pharmaview provides continually updated analysis on more than 2,100 drugs from more than 250 companies, covering 150 product classes and 14 therapy areas—complete with more than 1,200 product-level forecasts.

The new platform includes not only expanded coverage of the biopharmaceutical industry, but enhanced functionality including improved search capabilities and prominent graphical data. An easy-to-navigate interface that includes hyperlinked content points users to related industry, company and therapeutic-area analysis. Pharmaview subscribers have access to competitive assessment calls on current industry issues and Market Analyzer, a quantitative tool that allows users to track market sizes, assess barriers to market entry, quickly benchmark internal forecasts and analyze the potential of a licensing candidate.  

Members of the media may contact Lisa Osgood at losgood@dresources.com with data requests from the new Pharmaview platform.

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision ResourcesDecision Resources, Inc.Lisa Osgood

Christopher Comfort781-993-2606

781-993-2597losgood@dresources.com

ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline
2. Mylan to Appeal Court Decision in Generic Paroxetine Hydrochloride CR Case
3. FDAs Just Approved Monthly Drug Treatment, Vivitrol Could Be Game Changer, Says Countrys Largest Drug Treatment Recovery President, CRCs Jerry Rhodes; Provides Addicts One Decision A Month Instead of 30
4. Decision Resources Launches Analogue Tool To Help Pharmaceutical Companies Quickly Assess Market Opportunity
5. Business & Decision North America Announces the Successful Go-Live of Microsoft Dynamics AX at DeVilbiss Healthcare
6. Wise Sky Highlights Their Disappointment at Emergents Decision Not to Enter the China Market
7. Decision Resources Competitive Landscape Seminar Series: Biologics and Biosimilars on September 14, 2010 Will Help Pharmaceutical Companies Understand Market Opportunities for Biologics and Biosimilars
8. FDA Issues Assessments of the 510(k) Program and Use of Science in Decision-Making
9. Medco CEO to Present at the Sanford C. Bernstein & Co., LLC 26th Annual Strategic Decisions Conference 2010
10. Abbott Chairman and CEO Miles D. White to Present at Sanford Bernstein Strategic Decisions Conference
11. HIMSS Honors Memorial Healthcare System for Using TheraDoc(TM) Decision Support Technology to Achieve 97 Percent Compliance With Pediatric Asthma Quality Measures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 2017  Novartis today announced the publication of ... and Blood Institute (NHLBI) of the National Institutes ... with treatment-naïve severe aplastic anemia (SAA) achieved complete ... at the initiation of and concurrently with standard ... sequential treatment groups, or cohorts. Cohort 3 added ...
(Date:4/18/2017)... -- Cardinal Health (NYSE: CAH ) today is ... share (EPS) guidance and providing a preliminary view on ... this morning,s announcement of the planned acquisition of Medtronic,s ... Cardinal Health now believes that fiscal 2017 ... bottom of its previous guidance range of $5.35 to ...
(Date:4/18/2017)... 18, 2017 Viverae ® , a leader ... integration of IBM ® Watson Campaign Automation, implementing ... communications for a personalized experience. Through digital engagement, the ... health in real time. The enhanced experience drives engagement ... members, wherever they are in their journey to health. ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... 2017 , ... Journal of Oral Implantology – Tooth loss is ... dental health, including complications with speech, eating, and overcompensation of mouth due to the ... teeth. As the number of tooth replacements increase, it is imperative to design an ...
(Date:4/26/2017)... ... April 26, 2017 , ... Elisabete ... has been honored by Enterprising Women magazine as one of its 2017 Enterprising ... women business owners. Winners have demonstrated that they have fast-growth businesses, mentor or ...
(Date:4/26/2017)... ... 2017 , ... RawTrition now brings you BioEnergy which is a powder capsule ... , RawTrition is taking nutrients to the next level! The superfoods in ... raw form (unlike the synthetically made options that are on the market). , Founder ...
(Date:4/26/2017)... Gainesville, FL (PRWEB) , ... April 26, 2017 ... ... health and human performance, is proud to announce that it has received 510(k) ... cutting-edge technologies, the MyoCycle Home and the MyoCycle Pro. , Both devices are ...
(Date:4/25/2017)... , ... April 25, 2017 ... ... in Newport Beach, California, committed to raising awareness for Duchenne muscular dystrophy, ... from its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial in ...
Breaking Medicine News(10 mins):